FDA approval feels like a guarantee of safety, but it isn’t one. Drugs reach pharmacy shelves every year with risks that weren’t fully understood at approval, defects introduced during manufacturing, or warnings that didn’t adequately describe the danger, and a landmark 2024 California Supreme Court ruling changed how patients prove exactly that last category in court.
Quick answer: Defective drugs typically reach consumers through gaps in clinical testing, manufacturing errors during production, or inadequate warning labels. California recognizes three types of drug defect claims, design, manufacturing, and failure to warn, and a 2024 state Supreme Court decision (Himes v. Somatics) clarified exactly how patients can prove a stronger warning would have changed their treatment.
How Unsafe Drugs Pass the FDA Approval Process
FDA approval requires clinical trials showing a drug is reasonably safe and effective, but those trials have real limits: they typically run for a defined period, on a limited number of participants, and can’t always surface risks that only emerge after years of widespread use, in specific populations, or in combination with other medications. Some risks only become clear once a drug reaches millions of patients under real-world conditions the trial never tested. That’s why post-market surveillance exists, the FDA’s adverse event reporting system continues collecting reports from doctors, patients, and manufacturers after approval, and a drug that looked safe in trials can still be recalled or relabeled with new warnings years later once real-world data reveals problems the approval process missed. Financial pressure can compound the problem: a manufacturer racing a drug to market, or reluctant to fund the additional studies a safety signal calls for, doesn’t change what the law requires of them once a risk becomes apparent.
Manufacturing Defects
A drug can be perfectly safe as designed and still become dangerous through how it’s actually produced. Contamination, incorrect dosing during production, mislabeling, and cut corners in quality control can all turn an approved, well-designed medication into a defective product before it ever reaches a pharmacy. When a manufacturer knowingly ships a defective batch, or cuts corners on quality control that a reasonable manufacturer wouldn’t, that departure from the approved design or formula is generally what separates a manufacturing defect claim from a design defect claim, even though both can result in the same kind of injury to a patient.
The Three Types of Drug Defect Claims
California product liability law generally recognizes three distinct theories in a defective drug case. A design defect claim argues the drug itself is unreasonably dangerous even when manufactured exactly as intended, because its risks outweigh its benefits. A manufacturing defect claim, as described above, argues a specific batch or unit departed from the approved design during production. A failure-to-warn claim argues the drug’s labeling didn’t adequately disclose a known or knowable risk to prescribing physicians. These theories aren’t mutually exclusive, a single case can raise more than one, depending on what the evidence shows about how a particular drug caused harm. A blood thinner that fails to disclose a serious clotting or bleeding risk is a classic failure-to-warn scenario, while a contaminated batch of an otherwise safe medication is a manufacturing defect, and a drug pulled from the market entirely because its risks were found to outweigh its benefits for any patient is closer to a design defect claim. When a single medication turns out to have injured a large number of patients in the same way, these cases are sometimes consolidated into a mass tort or multidistrict litigation, which can affect how and when your individual case resolves.
Injured by a medication you were prescribed? We can help identify which type of claim applies to your case. Call (949) 535-1341 for a free consultation.
Failure-to-Warn Claims and the Learned Intermediary Doctrine
California follows the “learned intermediary doctrine,” meaning a drug manufacturer’s duty to warn generally runs to the prescribing physician, not directly to the patient, the idea being that the doctor is best positioned to weigh a medication’s risks against a specific patient’s needs. In July 2024, the California Supreme Court’s decision in Himes v. Somatics firmly upheld this doctrine while clarifying exactly how patients prove their case was affected by an inadequate warning. Rather than requiring proof that a stronger warning would have changed the physician’s own recommendation, the court adopted a two-step test: first, what would the physician have actually told the patient if given a stronger warning, and second, would an objectively reasonable patient in that situation have declined the treatment even if the doctor still recommended it. This matters because it means a patient isn’t necessarily out of luck just because their doctor says they’d have prescribed the drug anyway, the focus shifts to what a reasonable patient would have decided once properly informed.
Think a warning label didn’t tell you enough? Recent changes in California law may affect your case. Call (949) 535-1341 for a free case review.